- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05890963
10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults
Phase 1b Single Dose Clinical Trial of a Novel Long-Acting Bispecific Antibody in People With HIV to Inform Development for HIV Pre- and Post-Exposure Prophylaxis
This is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for > 24 weeks. This study will enroll PLWH to assess the safety, tolerability, and antiviral effect of bispecific and long-acting bNAbs, alone and in combination. The study will be conducted as a single center study at National Institute for Medical Research-Mbeya Medical Research Center (NIMR-MMRC) in Mbeya, Tanzania.
20 PLWH will be sequentially enrolled into one of 5 arms, each arm comprised of 4 participants. Sequential enrollment will occur in the following order:
- Arm 1 will receive standard daily oral ART.
- Arm 2 will receive a single dose of 10E8.4/iMab 600mg intravenous injection (IV).
- Arm 3 will receive a single dose of 10E8.4/iMab 600mg intramuscular injection (IM).
- Arm 4 will receive a single dose of 10E8.4/iMab 1800mg IV.
- Arm 5 will receive a single dose of combination therapy with both 10E8.4/iMab 1800mg IV and VRC07-523LS 1200mg IV.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Although global initiatives have made great strides in controlling the human immunodeficiency virus (HIV) pandemic, HIV and acquired immune deficiency syndrome (AIDS) continue to impact the lives and livelihoods of a significant portion of the population. In 2019, 38 million individuals were living with HIV and 690,000 died of AIDS-related causes. Despite extensive global efforts for disease control over the last 20 years, 1.7 million individuals contract HIV annually. Antiretroviral therapy (ART) reduces morbidity and mortality associated with HIV by suppressing viral replication but does not eradicate infection. There are barriers to universal ART use that include toxicities, costs, drug resistance, and the need for lifelong adherence. To overcome these barriers, HIV broadly neutralizing antibodies (bNAbs) represent a novel approach to HIV prevention and treatment.
The primary endpoint of change in viral load will be assessed at day 14. Participants will then transition to Step 2, during which all participants will take standard daily oral ART and have viral load monitored through Step 2 week 48.
Study Type
Enrollment (Estimated)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: David D. Ho, MD
- Phone Number: 212-304-6102
- Email: dh2994@cumc.columbia.edu
Study Contact Backup
- Name: Magdalena Sobieszczyk, MD
- Phone Number: 646-489-7775
- Email: mes52@cumc.columbia.edu
Study Locations
-
-
-
Mbeya, Tanzania
- Recruiting
- National Institute for Medical Research-Mbeya Medical Resarch Center
-
Contact:
- Marco Missanga, MD, MMed
- Phone Number: +255-25-250-6164
- Email: mmissanga@nimr-mmrc.org
-
Contact:
- Lucas Maganga, MD, MPH
- Phone Number: +255-25-250-6164
- Email: lmaganga@nimr-mmrc.org
-
Principal Investigator:
- Marco Missanga, MD, MMed
-
Sub-Investigator:
- Emanuel Kapesa, MD
-
Sub-Investigator:
- Elizabeth Danstan, MD
-
Sub-Investigator:
- Joel Mwakisisle, MD, MSc
-
Sub-Investigator:
- Agatha Urio, CO
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to read and write in Kiswahili and/or English
- Able and willing to provide written informed consent
- Passes Test of Understanding (TOU)
- Aged 18-50 years, inclusive
- Antiretroviral Therapy (ART)-naïve or no ART for > 24 weeks at the time of screening
- HIV RNA 1,000-100,000 copies/mL
- CD4 ≥ 500 cells/mm3
- Laboratory criteria at screening within protocol-specified limits for blood, chemistry and urinalysis
- Willing and able to participate in study visits and procedures for up to 50 weeks
- Willing and able to begin ART as directed during the study
- Willing and able to use barrier protection during sex with partners without HIV or partners with unknown HIV status throughout Step 1 and until viral suppression <200 copies/mL is confirmed in Step 2
Willing and able to adhere to the following contraception requirements:
- Participants who are able to become pregnant must agree to use at least one method of highly effective contraception if participating in sexual activity that could lead to pregnancy. This must begin at least 14 days prior to study enrollment.
- Participants who engage in sexual activity that could lead to their partner becoming pregnant and who are of reproductive potential must agree to use a barrier method of contraception to avoid pregnancy in a sexual partner of reproductive potential. The barrier method must be used for the duration of the study.
Exclusion Criteria:
- Weight >100 kg
- Previous receipt of humanized or human monoclonal antibody whether licensed or investigational (other than for the prevention and/or treatment of SARS-CoV2/COVID-19)
- History of viral failure on two or more ART regimens
- Planned or anticipated need for enfuvirtide, maraviroc, fostemsavir, or ibalizumab for antiretroviral therapy.
- AIDS-defining illness, as enumerated by the WHO Stage 3 or 4, within the six months prior to enrollment
- Ongoing oral thrush
- Active injection or other recreational drug use within the previous 12 months that, in the opinion of the investigator, would impede the participant's ability to safely and consistently adhere to the study protocol
- History of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis in the 2 years prior to enrollment.
- History of chronic urticaria requiring daily treatment
- Known active hepatitis B virus infection or positive hepatitis B surface antigen at any time in the past
- Known active hepatitis C virus infection or positive hepatitis C antibody at any time in the past
- Untreated syphilis
- Estimated GFR < 50 mL/min within the past 90 days
- Pregnant or breast-feeding
- Receipt of licensed vaccine or other investigational study agent within 28 days prior to enrollment or any past participation in an investigational HIV vaccine study with receipt of active product
- Current or planned participation in another interventional clinical trial during the study period, including clinical trials of investigational new drugs or investigating a new application for an approved medication
- Chronic or recurrent use of medications that modify host immune response, such as oral steroids, parenteral steroids, or cancer chemotherapy (note: locally-acting medications-such as inhaled, topical, or intra-articular steroids-are allowed)
- Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the participant including, but not limited to: diabetes mellitus type I, chronic hepatitis, renal failure; OR clinically significant forms of: drug or alcohol abuse, mental illness, severe asthma, autoimmune disease, decompensated psychiatric disorders, hypertension, heart disease, or cancer
- Any medications that, in the opinion of the investigator, would preclude intramuscular injections
- Study site employee
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Arm 1: Oral ART
Participants will receive standard daily oral ART.
|
ART is a combination of three or more drugs from different classes of antiretroviral medication.
Other Names:
|
Experimental: Arm 5: Combination 10E8.4/iMab and VRC07-523LS therapy
Participants will receive a single dose of combination therapy with both 10E8.4/iMab
1800mg IV. and VRC07-523LS 1200mg IV.
|
10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity.
10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
Other Names:
VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope.
VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.
Other Names:
|
Experimental: Arm 2: 10E8.4/iMab 600mg IV.
Participants will receive a single dose of 10E8.4/iMab
600mg IV.
|
10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity.
10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
Other Names:
|
Experimental: Arm 3: 10E8.4/iMab 600mg IM.
Participants will receive a single dose of 10E8.4/iMab
600mg IM.
|
10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity.
10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
Other Names:
|
Experimental: Arm 4:10E8.4/iMab 1800mg IV.
Participants will receive a single dose of 10E8.4/iMab
1800mg IV.
|
10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity.
10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Grade 3 or higher antibody-related reactogenicity and adverse events
Time Frame: Up to Week 48 in Step 2
|
Includes potentially life-threatening, or fatal events.
|
Up to Week 48 in Step 2
|
Change in plasma HIV RNA from day 0 to day 14
Time Frame: Day 0 and Day 14 in Step 1
|
Viral RNA copies/mL will be measured.
|
Day 0 and Day 14 in Step 1
|
Proportion of participants with HIV RNA < 50 copies/mL at day 14
Time Frame: Up to Day 14 in Step 1
|
Percentage of participants will be calculated.
|
Up to Day 14 in Step 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportions of participants with HIV RNA <50 copies/mL
Time Frame: Up to Week 48 in Step 2
|
Percentage of participants will be calculated.
|
Up to Week 48 in Step 2
|
Proportions of participants with HIV RNA < 200 copies/mL
Time Frame: Up to Week 48 in Step 2
|
Percentage of participants will be calculated.
|
Up to Week 48 in Step 2
|
Proportions of participants with HIV RNA <1000 copies/mL
Time Frame: Up to Week 48 in Step 2
|
Percentage of participants will be calculated.
|
Up to Week 48 in Step 2
|
Peripheral HIV RNA
Time Frame: Up to Week 48 in Step 2
|
Serum level of viral RNA (copies/mL) will be measured.
|
Up to Week 48 in Step 2
|
Plasma level of 10E8.4/iMab
Time Frame: Up to Week 48 in Step 2
|
Serum level of 10E8.4/iMab
(ug/mL) will be measured.
|
Up to Week 48 in Step 2
|
Plasma level of VRC07-523LS
Time Frame: Up to Week 48 in Step 2
|
Serum level of VRC07-523LS (ug/mL) will be measured.
|
Up to Week 48 in Step 2
|
CD4 receptor occupancy
Time Frame: Up to Week 48 in Step 2
|
The percentage of CD4 cells that bind to 10E8.4/iMab will be measured.
|
Up to Week 48 in Step 2
|
HIV reservoir size
Time Frame: Up to Week 48 in Step 2
|
Will measure HIV DNA in copies/million cells.
|
Up to Week 48 in Step 2
|
Neutralization sensitivity of 10E8.4/iMab
Time Frame: Up to Week 48 in Step 2
|
Half-maximal inhibitory concentration (IC50) will be measured.
|
Up to Week 48 in Step 2
|
Neutralization sensitivity of VRC07-523LS
Time Frame: Up to Week 48 in Step 2
|
Half-maximal inhibitory concentration (IC50) will be measured.
|
Up to Week 48 in Step 2
|
Presence of anti-bNAb antibodies
Time Frame: Up to Week 48 in Step 2
|
The anti-drug antibody titer in serum will be measured.
|
Up to Week 48 in Step 2
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marco Missanga, MD, NIMR-MMRC
- Principal Investigator: David D. Ho, MD, Columbia University Irving Medical Center (IND Sponsor)
- Study Chair: Trevor A. Crowell, MD, PhD, The U.S. Military HIV Research Program (MHRP)
Publications and helpful links
General Publications
- Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7. doi: 10.1073/pnas.94.24.13193.
- Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997 Nov 14;278(5341):1295-300. doi: 10.1126/science.278.5341.1295.
- Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, Chisholm P. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol. 1992 Sep 1;149(5):1779-87.
- Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012 Nov 15;491(7424):406-12. doi: 10.1038/nature11544. Epub 2012 Sep 18.
- Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, Gajjar MR, Sun M, Seaman MS, Padte NN, Ho DD. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell. 2016 Jun 16;165(7):1621-1631. doi: 10.1016/j.cell.2016.05.024.
- Mahomed S, Garrett N, Capparelli EV, Osman F, Harkoo I, Yende-Zuma N, Gengiah TN, Archary D, Samsunder N, Baxter C, Mkhize NN, Modise T, Carlton K, McDermott A, Moore PL, Karim QA, Barouch DH, Fast PE, Mascola JR, Ledgerwood JE, Morris L, Abdool Karim SS. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. J Infect Dis. 2022 Aug 26;226(3):510-520. doi: 10.1093/infdis/jiac041.
- Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009 Feb;53(2):450-7. doi: 10.1128/AAC.00942-08. Epub 2008 Nov 17.
- Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010 Jul 31;376(9738):355-66. doi: 10.1016/S0140-6736(10)60832-X.
- Jaworski JP, Cahn P. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. Lancet HIV. 2018 Dec;5(12):e723-e731. doi: 10.1016/S2352-3018(18)30174-7. Epub 2018 Sep 21.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AAAU5207
- W81XWH-18-2-0040 (Other Grant/Funding Number: DAIDS/NIAID/NIH)
- RV584 (Other Identifier: WRAIR IRB)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1-infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on ART
-
Laboratoires NEGMAUnknown
-
Asahi Kasei Pharma CorporationCompletedPostoperative Stage II/III Colon CancerJapan
-
University of DerbyCompletedPerinatal Mental HealthUnited Kingdom
-
Florida State UniversityCompleted
-
Hampton VA Medical CenterTerminatedPost-traumatic Stress Disorder | Stress Disorder, Post-TraumaticUnited States
-
AIDS Clinical Trials GroupNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV Infection | TuberculosisUnited States, Peru, Kenya, Malawi, Uganda, Brazil, South Africa, Zimbabwe, India, Thailand, Botswana, Haiti, Zambia
-
Radboud University Medical CenterUniversitas TarumanagaraCompletedDepressive Symptoms | Well-beingIndonesia
-
OHSU Knight Cancer InstituteOregon Health and Science University; National Center for Complementary and...Not yet recruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Laboratoires FILLMEDCompleted
-
Fred Hutchinson Cancer CenterNational Institute on Drug Abuse (NIDA); University of Washington; Seattle Children... and other collaboratorsCompleted